Videos - Abzena
Manufacturing & Cell Line Development at Abzena

Filter by year

Filter by topic

December 2015: Abzena boss pleased with “synergistic” TCRS deal

October 2016: Abzena CEO: Roche’s Adheron takeover increases chance of revenues

October 2016: Executive Interview – Abzena

September 2016: Abzena boss eyes expansion after PacificGMP purchase

June 2015: Abzena chief: 2015 was a “transformational year”

June 2015: Abzena chief exec looks to build on “transformational” year

Abzena’s (LON:ABZA) first set of full-year results since listing on the stock market highlight a “transformational period” for the company, says chief executive John Burt. Speaking to Proactive, the CEO said the firm is gaining traction with its product mix after generating revenues of £5.7mln in the 12 months to March 31 but will keep […]

May 2015: Abzena CEO ‘scanning the horizon’ for new acquisitions

John Burt, chief executive of Abzena (LON:ABZA), tells Proactive Investors the company continues to be on the lookout for new acquisitions. It follows the news its subsidiary Antitope has agreed to design and run a special study that will help privately-owned biotech Apitope understand patient responses to treatment with ATX-F8-117. Burt likens Abzena to duck […]

April 2015: Abzena expects revenue flows as proprietary antibodies enter clinical development

AIM listed life sciences technology company, Abzena (LON:ABZA), reports a series of positive developments for its composite human antibodies. CEO, John Burt, tells Proactiveinvestors that two of their partners have started clinical trials using antibodies developed by their research teams. One partner is developing therapies for chemotherapy induced anaemia, whilst a major US firm is […]

March 2014: An Overview of Technologies for Antibody-drug Conjugation – John Burt

John Burt, CEO of PolyTherics, speaks on ‘An Overview of Technologies for Antibody-drug Conjugation’ at One Nucleus’ Life Science Leadership Series – Antibody Based Therapeutics conference at Babraham Research Campus.

Interested in our services? Get In Touch